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ABSTRACT. The optimum composition and concentration
of crystalline amino acid solutions necessary for growth and
brain maturation in critically ill infants requiring total paren-
teral nutrition (TPN) are unknown. Either an excess or a
deficiency of amino acids could theoretically impair normal
brain development in the neonate. The purpose of this study
was to compare the toxicity and efficacy of two intravenous
amino acid solutions, Neopham, modeled after the amino acid
pattern found in human breast milk, and Aminosyn, a marketed
product, designed for general usage.
Sixteen infants and children requiring continuous intrave-
nous nutrition for at least 7 days received the Neopham amino
acid solution, and eight infants and children received the Ami-
nosyn amino acid solution as part of a total parenteral nutrition
regimen which included glucose, the fat emulsion Intralipid, as
well as routine mineral and vitamin additives.
There were no significant differences in mean gestational
age, body weight, postnatal age, or mean daily nutrient intake
between the patients receiving Aminosyn or Neopham. The
daily nitrogen intake, excretion, and retention were similar in
both groups. In addition, there were no statistically significant
differences in either hematological or biochemical parameters
between the two study groups.
The plasma levels of three essential amino acids, isoleucine,
methionine, and valine, rose significantly higher in the Ami-
nosyn-treated patients. The plasma levels of all the essential
amino acids increased in both study groups. (Journal of Par-
enteral and Enteral Nutrition 11:368-377, 1987)
Glycine was the only nonessential amino acid whose
plasma level was significantly higher in the Aminosyn-
treated children. The levels of the remaining nonessen-
tial amino acids either increased or decreased, depending
upon the amino acid solution infused. In general, the
plasma aminogram analyses reflected the composition of
the respective parent solution.
On the basis of this study, Neopham appears to be as
effective as Aminosyn in a pediatric TPN regimen in
terms of weight gain, nitrogen balance, and clinical con-
dition. No serious side effects were observed with either
amino acid solution. Finally, plasma aminograms appear
to reflect the amino acid composition of the infused
solution.
Total parenteral nutrition (TPN) administered via a
central or peripheral vein has gained wide acceptance for
use in selected pediatric and adult patients. A typical
TPN regimen includes glucose, protein (supplied in the
form of crystalline amino acids), a fat emulsion, vitamins,
minerals, and trace elements. Such combinations of nu-
trients have proven very effective in totally supplying
critically ill infants with the nutritional support neces-
sary for growth, when enteral feedings are not feasi-
ble .2-5 However, definitive studies delineating the opti-
mum composition and concentration of crystalline amino
acid solutions necessary for growth6-9 and brain
maturationlo-13 have not been performed. Amino acid
deficiency or excess in the developing neonate could
possibly impair normal development of the brain.14-16
The purpose of this study was to compare the toxicity
and efficacy of Neopham (KabiVitrum, Inc.) with Ami-
nosyn (Abbott Laboratories) as a nitrogen source in a
TPN protocol in infants and children. The results doc-
ument that Neopham is as effective as aminosyn in
TABLE I
Composition of Neopham and Aminosyn amino acid solutions
° Denotes significant difference.
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promoting growth, as measured by weight gain and pos-
itive nitrogen balance, and that no adverse side effects
of toxicity can be attributed to Neopham.
MATERIALS AND METHODS
Twenty-four infants and children, from one day to 10
yr old, who required continuous TPN for at least 7 days
were studied. Patients receiving any enteral nutrition,
those with a diagnosis of cardiac failure, renal insuffi-
ciency, diabetes mellitus, untreated infections, and those
receiving concurrent corticosteroid medication were ex-
cluded from the study.
After obtaining parental informed consent, the follow-
ing preinfusion tests were performed: urine-urea-nitro-
gen and urine osmolalitv, plasma amminogram analysis,
complete blood count with differential white blood cell
count, platelet count, blood-urea-nitrogen t ~L’:~ 1, serum
uric acid, albumin, total protein, cholesterol, triglycer-
ides, total bilirubin, alkaline phosphatase, lactic acid
dehydrogenase (LDH ), serum glutamic oxaloacetic trans-
aminase (SGOT), ammonia, magnesium, and osmolality.
TABLE II
- 
Demographic data of patients administered Aminosyn (n = 8) or Neopham (n = 16) as the amino acid source in a TPN regimen
° D = days, M = months, Y = years.
TABLE III
Gestational age, body weight. and postnatal age of the Aminosyn- and Neopham-treated patients
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Patients were randomly assigned in a 1:2 ratio to
receive TPN solutions with Aminosyn (Abbott Labora-
tories), designated group 1. or Neopham (KabiVitrum,
Inc. ~, designated group 2. either by periperhal or central
venous routes. The amino acid composition of Aminosyn
and Neopham is listed in Table 1. The solutions for
centrally administered TPN consisted of 25% glucose
and 3.5% crystalline amino acids, whereas the peripheral
regimen consisted of 12.5% glucose and 2.5% crystalline
amino acids. Intralipid was provided to a maximum of
40% of dailv caloric intake. All TPN solutions contained
routine vitamin and mineral additives.
Daily observations included vital signs, weight, urine
tests, and a report of adverse symptoms or side effects.
Estimated caloric requirements and nitrogen balance
were computed daily. At weekly intervals, blood chem-
istries were repeated. Blood ammonia levels and plasma
aminograms were analyzed twice weekly.
Nitrogen intakes were calculated for each day of TPN
from the recorded infusions of amino acids. One gram of
amino acids as Aminosyn provided 157.7 mg of nitrogen,
1.0 gram of amino acids as Neopham provided 143.1 mg
of nitrogen. The amount of nitrogen excreted was meas-
ured to the nearest 1.0 mg on each day in which urine
collections were successfully obtained. Approximate ni-
trogen balances were determined as the differences be-
tween nitrogen intake and nitrogen excretion. Nitrogen
losses from nasogastric drainage, wounds, and fecal and
enterostomy output were not quantified.
The data were subjected to two separate statistical
analyses due to the heterogeneity of the population stud-
ied. The first analysis involved the 16 patients who were
less than 28 days old at entrance into the study protocol
(Neonatal Analysis). The second evaluation (Total Pa-
tient Analysis) pertained to all 24 patients; the age range
of the eight additional patients spanned 1 month to 10
years. Data from the first 15 days of TPN formed the
basis of this study.
RESULTS
Demographic Data
Demographic data (mean ± SD) of the eight patients
who received Aminosyn (group 1) and the 16 patients
who received Neopham (group 2) as the amino acid
component of a total hyperalimentation nutritional reg-
imen are presented in Table II.
Neonatal Analysis. There were no significant differ-
ences in mean gestational age, body weight, or postnatal
age at entrance into the study ( n = 16) between the
neonates receiving either Neopham ( n = 10) or Amino-
syn (n = 6) (Table III). A mean gestational age of 38.5
± 1.8 weeks, a mean initial body weight of 2.75 ± 0.66
kg, and a mean postnatal age of 5.0 ± 5.0 days were
recorded for the Aminosyn (group 1) patients, while the
respective values for the Neopham (group 2) patients
was 37.1 ± 2.5 weeks, 2.5 ± 0.52 kg, and 5.7 ± 7.5 days.
Analysis of Older Infants and Children. There were no
significant differences in mean body weight [5.6 ± 3.32
kg (Aminosyn) us 11.87 ± 6.64 kg (Neopham)] and age
at entrance into the study protocol [5.75 ± 6.01 months
(Aminosyn) us 57.16 ± 51.2 months (Neopham)] between
the two patient groups (Table III).
Nutritional Data
The mean daily nutrient intakes of the group 1 (Ami-
nosyn) and group 2 (Neopham) patients are presented in
Table IV. There were no significant between- or within-
TABLE IV
Mean nutrient intake in patients who received Aminosyn (group 1) or Neopham (group 2)
° 
p values calculated by repeated measures analysis of variance.
TABLE V
Mean nitrogen balances data of patients who received either Aminosyn (group 1) or Neopham (group 2)
. 
p values calculated by one-way analysis of variance.
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TABLE VI I
Mean plasma concentrations of essential amino acid.s (p.moljliter) in neonates u.ho received either AminOS)7J or Neopham. (n = 16)
~~~~_~ ~_ ~ ~~ ~ ~ ~~~ 
_~
° Represents normal values recalculated from Ghadimi and Pecora.&dquo;
TABLE VII
Mean plasma concentrations of essential amino acids (tLmol/Itter) in patients who received either Aminosyn or Neopham (n = 24)
° Represents normal values recalculated from Ghadimi and Pecora. 17 
- _ __ __ - _ _ _ _ _ _ - ___-
group differences in dextrose, Intralipid, amino acid, or
total energy intake (expressed as kcal/kg/day) between
the group 1 and group 2 patients.
Neonatal Analysis. The group 1 (Aminosyn) patients
received 56.8 ± 8.7 kcal/kg/day of dextrose, 24.6 ± 9.2
kcal/kg/day of Intralipid and 11.7 ± 3.4 kcal/kg/day of
amino acids in comparison with the group 2 (Neopham)
patients who received 57.6 ± 8.5 kcal/kg/day of dextrose,
23.7 ± 11.3 kcal/kg/day of Intralipid, and 11.3 ± 3.3
kcal/kg/day of amino acids. The group 1 infants received
an average of 2.92 g/kg/day of aminosyn. while the group
2 infants received 2.84 g/kg/day of Neopham. There were
no significant differences in daily energy or amino acid
intakes between the Aminosyn and Neopham neonatal
patient groups.
Total Patient Analysis. The mean daily° intake of dex-
trose was 54.1 z- 12.5 kcal/kg/day, of Intralipid 26.6 ±
10.5 kcal/kgjday, and of amino acids it- 3.3 kcal/kg/
day in the group 1 (Aminosyn) patients. The mean daily
intake in the group 2 (Neopham) patients was 59.0 ±
19.2 kcal (kg/day of dextrose. 21.1 ± 12.2 kcal/kgjday of
Intt’alipicl, and 10.7 ± 4.4 kcaljkg/da~ of amino acids.
The mean daily intake of Aminosyn was 2.75 ± 0.8 g/
kg/day in the group 1 patients, and 2.67 ± 1.1 g/kg/day
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TABLE VIII
Mean plasma concentrations of nonessential amino acids (AmoillitRr) in neonates who received either Aminosyn or Neopham (n = 16)
° Represents normal values recalculated from Ghadimi and Pecora. 17
in the group 2 patients. These differences were not
statistically significant.
Nitrogen Balance
The mean daily nitrogen intake, excretion, balance
and percent retention are presented in Table V.
Neonatal Analysis. The mean daily nitrogen intake in
the group 1 (Aminosyn) patients was 476 ± 119 mg/kg/
day, and the mean nitrogen excretion was 137 ± 63 mg/
kg/day for a positive mean balance of 340 mg/kg/day.
This represents a retention of 71.8 ± 8.2%. The mean
daily nitrogen intake in the group 2 (Neopham) patients
was 405 ± 120 mg/kg/day, and the mean excretion was
120 ± 53 mg/kg/day, for a positive mean nitrogen balance
of 285 ± 135 mg/kg/day, or a mean retention of 70.4 ±
18.2%. The differences in intake, excretion, balance, and
percent retention were not significantly different.
Total Patient Analysis. The mean daily nitrogen intake
in the group 1 (Aminosyn) patients was 458 ± 107 mg/
kg/dav, and the mean nitrogen excretion was 153 ± 61
mg/kg/day, resulting in a net balance of 306 ± 100 mg/
kg/day. The mean retention was 66.8 ± 13.0%. Similarly,
the values for the group 2 (Neopham) patients were 393
± 103 mg/kg/day nitrogen intake and 128 ± 59 mg/kg/
day nitrogen excretion, representing a net balance of 246
± 117 mg/kg/day, or a retention of 67.2 ± 16.8%. These
differences were not statistically significant.
Body Weight
Two of eight patients in the Aminosyn group lost
weight over the course of the TPN therapy, while three
of 14 patients in the Neopham study group lost weight
during TPN.
Neonatal Analysis. The Aminosyn patients had an
initial mean body weight of 2.75 ± 0.53 kg and a final
mean weight of 2.94 ± 0.41 kg, resulting in a mean
percent weight increase of 0.87 ± 2.33/day. In contrast.
the Neopham patients had an initial mean body weight
of 2.5 ± 0.48 kg, and a post-study mean weight of 2.56 ±
0.45 kg, which represents a mean percent weight increase
of 0.32 ~- 3.79/day. These differences between the study
groups were not statistically significant.
Total Patient Analysis. The group 1 Aminosyn patients
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had an initial mean body weight of 3.47 ± 1.89 kg, which
increased to a final mean body weight of 3.6 ± 1.67 kg,
with a mean percent increase of 0.65 ± 2.36/day. The
Neopham study group had an initial mean body weight
of 4.5 ± 3.96 kg. and a final mean body weight of 4.88 ±
4.68 kg. resulting in a mean percent increase of f_~.4 i ±
3.47/day. These changes were not statistically signifi-
cant.
TABLE IX
Mean plasma concentrations of nonessential amino acids (JJ,mol/liter) in patients who received either Aminosyn or Neopham <n = 24)
Represents normal values recalculated from Ghadimi and Pecora.&dquo;
TABLE X
Mean serum alkaline phosphatase, total and direct bilirubin, LDH, and SGOT in neonates treated with Aminosyn and Neopham (n = 16)
* Values in parentheses represent normal values.
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Plasma Aminograms (Essential Amino Acids) >
The plasma aminogram data for essential amino acids
are presented in Tables VII and VII for the neonatal and
total patient analyses, respectively. P-Values are listed
for both between-group (Neopham L’S Aminosyn) and
within-group (changes during the course of the study
period) analvses.
,Neonatal Analysis. Significant between-group differ-
ences were found for three amino acids, namely, isoleu-
cine, methionine, and valine. Significant within group
increases occurred with isoleucine, leucine, methionine,
and valine in both the Aminosyn and Neopham patient
groups. The levels of all the amino acids increased in
both study groups (Table VI).
Total Patient Analysis. The levels of all the amino
TABLE XI
Mean serum alkaline phosphatase, total and direct bilirubin, LDH and SGOT in patients treated with (Aminosyn or Neopham (n = 24)
° Values in parentheses represent normal values.
TABLE XII
BUN, plasma ammonia, serum total protein, and albumin levels in neonates treated with Aminosyn or Neopham (n = 16)
------------------- -- 
~ _ _
° Values irn parentheses represent normal values.
TABLE XIII
BUN, plasma ammonia, serum total protein, and albumin levels in patients treated with Aminosyn or Neopham (n = 24)
° Values in parentheses represent normal values.
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TABLE XIV
Mean serum sodium, chloride, potassium. calcium. and magnesium ion neonates treated u-ith A minosyn or Neopham (n = 16)
° Values in parentheses represent normal values.
TABLE XV
Mean serum sodium, chloride, potassium, calcium, and magnesium levels in patients treated with A minosyn or Neopham (n = 24)
° Values in parentheses represent normal values.
acids increased in both study groups. Between- and
within-group analyses were identical to those of the
neonatal analysis for the essential amino acids (Table
VII).
Plasma Aminograms (Nonessential Amino Acids)
The plasma aminogram analysis for the non-essential
amino acids is presented to Table VIII (neonatal analy-
sis) and Table IX (total patient analysis).
Neonatal Analysis. The only amino acid which was
significantly different between the two study groups was
glycine. Significant within-group changes occurred with
a number of amino acids. Significantly decreased levels
of cystine occurred in the Aminosyn-treated patients.
while tyrosine decreased significantly in both the Ami-
nosyn and Neopham groups. Significant increases oc-
curred in aspartic acid, glutamic acid. glutamine, argi-
nine, glycine, and proline in both patient groups. Histi-
dine, alanine. and serine increased during the course of
therapy in both groups. but not significantly. Taurine
levels decreased in both the Aminosyn and Neopham
groups, but not significantly (Table VIII).
Total Patient Analysis. The only significant between-
group difference was in glycine concentration, which was
significantly elevated in the Aminosyn-treated patients.
Within-group significant increases occurred in cystine in
the Neopham patients, while aspartic acid, glutamic acid.
alanine, arginine, and glycine were significantly in-
creased in both the Neopham and Aminosyn grmlp’ 111
the Aminosyn groups, cystine was significant [y decrea:--ed.
Taurine and tyrosine decreased in bath groups, but not
significantly; in contrast, histidine, glutamine. ~3roline,
and serine were increased insignificantly in both the
Aminosyn and neopham groups (Table IX).
Hematotogical Data
Neonatal ,4nalp.;I.;. There were no significant differ-
ences between treatment groups for any of the hemato-
logical parameter< studied.
Total Patient .4.’101.B ,i.-: There were no significant dif-




Mean. standard deviation, and significance levels for
between- and within-group analysis of biochemical data
are presented in Tables X through XVII.
Neonatal Analysis. There were no significant between-
group differences in alkaline phosphatase, LDH, SGOT,
total and direct bilirubin. BVithin-group significant de-
creases were seen in alkaline phosphatase, LDH, and
total bilirubin for both the Aminosyn and Neopham
groups (Table X).
There were no significant between-group differences
in BUN, plasma ammonia, serum total protein, or albu-
min levels. Within-group analyses showed a significant
increase in total protein and albumin in the Neopham
treatment group (Table XII).
There were no significant between-group differences
in serum sodium, chloride, potassium, calcium, or mag-
nesium levels in either study group. Serum sodium, cal-
cium, and magnesium increased significantly in both
groups during the course of the study (Table XIV).
There were no significant between-group differences
in serum glucose, triglyceride, cholesterol, or phosphorus
levels; however, initial uric acid values were significantly
elevated in the Neopham group. Within-group signifi-
cant increases occurred in cholesterol levels, while uric
acid levels significantly decreased in both treatment
groups (Table XVI).
Total Patient Analysis. There were no significant be-
tween-group differences in alkaline phosphatase, LDH,
SGOT, and total and direct bilirubin. There were signif-
icant within-group decreases in LDH and total bilirubin
in both treatment groups, and in alkaline phosphatase
in the Neopham treatment group (Table XI).
There were no significant between-group differences
in BUN, plasma ammonia, serum total protein, or albu-
min levels. Within-group analyses indicated a significant
increase in ammonia, total protein, and albumin levels
in the Neopham and Aminosyn treatment groups (Table
XIII).
There were no significant between-group differences
in serum sodium, chloride, potassium, calcium, or mag-
nesium levels in either group. Calcium and magnesium
increased significantly in both groups (Table XV).
There were no significant between group differences
in serum glucose, triglyceride, cholesterol, phosphorus,
or uric acid levels. Significant within-group increases
TABLE XVI
Mean serum glucose, triglycerides, cholesterol, phosphorus, and uric acid levels in neonates treated with Aminosyn or Neopham (n = 16)
.. Values in parentheses represent normal values.
TABLE XVII
Mean serum glucose, triglycerides, cholesterol, phosphorus, and uric acid levels in patients treated with Aminosyn or Neopham (n = 24)
____f__~ ___ ~ s__ ___ - ___ -------
’Values in parentheses represent normal values.
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occurred in cholesterol levels, whereas uric acid de-
creased significantly in both treatment groups (Table
XVII).
CONCLUSIONS
Although nitrogen balances have to be viewed with
caution in this study due to the difficulty with quanti-
tative urine collections and the unaccounted losses of
nitrogen through non-urinary routes, the similarity in
nutrient intake, weight gain, and nitrogen retention in
both groups indicates that Neopham and Aminosyn are
equally effective in promoting growth in a TPN program.
The weight increase per day in the Neopham neonatal
group was lower (0.32 ± 3.79% compared to 0.87 ± 2.33%
in the Aminosyn group), but this change was not statis-
tically significant. The nitrogen balance data was also
slightly lower in the Neopham group (285 ± 135 mg/kg/
day, 70.4% retention, compared with the Aminosyn
group, 340 ± 71.8 mg/kg/day, 7.18% retention).
The plasma aminogram analyses reflected, in general,
the composition of the respective parent solutions. All of
the essential amino acids (isoleucine, leucine, lysine,
methionine, phenylalanine, threonine, and valine) in-
creased over the time course of the study in both treat-
ment groups. Significant increases in isoleucine, methi-
onine, and valine in the Aminosyn vs the Neopham
treatment group probably reflect the higher concentra-
tion of these amino acids in the Aminosyn preparation.
Four of the essential amino acids (isoleucine, leucine,
methionine, and valine) increased significantly in both
treatment groups over the course of the study.
Analysis of the nonessential amino acids revealed a
significantly greater increase in glycine in the Aminosyn
group, probably because of the higher concentration of
this amino acid in Aminosyn. Significant changes oc-
curred in cystine, tyrosine, aspartic acid, glutamic acid,
glutamine, arginine, glycine, and proline. Decreased
plasma levels of cystine in the Aminosyn patients prob-
ably reflect the lack of cysteine in the Aminosyn solution.
Levels of taurine decreased over the course of the study;
neither amino acid solution contains taurine. Neopham
contains 410 mg/dl of aspartic acid and 710 mg/dl of
glutamic acid, whereas Aminosyn contains neither. How-
ever, the two patient groups had similar plasma levels of
these amino acids.
Therefore, it appears that the serum amino acid profile
of these patients closely reflects the amino acid compo-
sition of the parent solution.
Hemoglobin, hematocrit, and the erythrocyte count all
significantly decreased during the course of the study.
Also, white blood cell count, especially neutrophils and
immature bands, decreased. In contrast, the lymphocyte
and platelet counts increased significantly. There is no
obvious explanation for these changes; however, frequent
blood sampling may explain the decreases in hemoglobin,
hematocrit, and erythrocyte count.
The increase in alkaline phosphatase, total protein,
and albumin were significant but not readily explainable,
although all of these changes could result from the TPN
therapy.
On the basis of this limited study, it appears that
Neopham is as effective as Aminosyn in a TPN regimen
in terms of weight gain, nitrogen balance, and overall
clinical well-being. No serious side effects were seen with
either amino acid solution. In addition, plasma amino-
grams appear to be a direct reflection of the amino acid
composition of infused solution.
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